Literature DB >> 22533653

Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines.

Marie Krousel-Wood1, Paul Muntner, April Carson, Amanda H Anderson, Erin Delaune, William C Cushman, Jeffrey A Cutler, Linda B Piller, Gary A Goforth, Paul K Whelton.   

Abstract

Medication prescribing practice changed following the publications of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) in 2002 and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) in 2003. Few data are available on changes in hypertension control rates for patients initiating antihypertensive treatment before and after these publications. The authors compared systolic and diastolic blood pressure (SBP and DBP) levels and hypertension control (SBP <140 mm Hg and DBP <90 mm Hg) rates in patients initiating antihypertensive treatment in a large managed care organization during 2 time periods: July 1, 2001, to June 30, 2002 (n=322); and July 1, 2003, to June 30, 2004 (n=323). The blood pressure reduction associated with antihypertensive medication initiation was similar in 2001-2002 and 2003-2004 (-11.9 and -10.5 mm Hg, respectively, P=.251 for SBP; -6.9 and -5.9 mm Hg, respectively, P=.160 for DBP). The mean SBP and DBP prior to treatment were significantly lower in 2003-2004 vs 2001-2002 (145.4 vs 151.3 mm Hg, P<.001 for SBP; 87.6 vs 90.1 mm Hg, P<.002 for DBP). Hypertension control rates increased from 38.0% to 50.2% (P=.005) from 2001-2002 to 2003-2004. Lower pretreatment SBP and DBP explained hypertension control improvement over time. In this real-world clinic population, antihypertensive treatment was initiated at lower blood pressure levels following publication of ALLHAT and JNC 7, resulting in substantial improvements in hypertension control rates.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22533653      PMCID: PMC4545243          DOI: 10.1111/j.1751-7176.2012.00609.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  15 in total

1.  Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.

Authors:  Fagen Xie; Diana B Petitti; Wansu Chen
Journal:  Am J Hypertens       Date:  2005-04       Impact factor: 2.689

2.  Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.

Authors:  Michael E Ernst; Barry L Carter; Chris J Goerdt; Jennifer J G Steffensmeier; Beth Bryles Phillips; M Bridget Zimmerman; George R Bergus
Journal:  Hypertension       Date:  2006-01-23       Impact factor: 10.190

3.  Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.

Authors:  Jackson T Wright; J Kay Dunn; Jeffrey A Cutler; Barry R Davis; William C Cushman; Charles E Ford; L Julian Haywood; Frans H H Leenen; Karen L Margolis; Vasilios Papademetriou; Jeffrey L Probstfield; Paul K Whelton; Gabriel B Habib
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

4.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

5.  Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States.

Authors:  Randall S Stafford; Veronica Monti; Curt D Furberg; Jun Ma
Journal:  Hypertension       Date:  2006-06-19       Impact factor: 10.190

6.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

7.  Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  Hypertension       Date:  2003-08-18       Impact factor: 10.190

8.  Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.

Authors:  Randall S Stafford; Curt D Furberg; Stan N Finkelstein; Iain M Cockburn; Tseday Alehegn; Jun Ma
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

9.  Antihypertensive prescribing practices: impact of the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Authors:  Marty S Player; James M Gill; Heather Bittner Fagan; Arch G Mainous
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

10.  Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio.

Authors:  Aluísio J D Barros; Vânia N Hirakata
Journal:  BMC Med Res Methodol       Date:  2003-10-20       Impact factor: 4.615

View more
  9 in total

1.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2012

2.  Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018.

Authors:  Paul Muntner; Shakia T Hardy; Lawrence J Fine; Byron C Jaeger; Gregory Wozniak; Emily B Levitan; Lisandro D Colantonio
Journal:  JAMA       Date:  2020-09-22       Impact factor: 56.272

3.  Treating Refractory Hypertension: Renal Denervation With High-Resolution 3D-Angiography.

Authors:  Eduardo Alegria-Barrero; Rodrigo Teijeiro; Miguel Casares; Mercedes Vega; Marco A Blazquez; Ramon Martos; Carlos De Diego; Raúl Moreno; Miguel A San Martin
Journal:  Res Cardiovasc Med       Date:  2013-05-20

4.  Pilot Enhancement of the Arthritis Foundation Exercise Program with a Healthy Aging Program.

Authors:  Elizabeth A Schlenk; Joni Vander Bilt; Wei-Hsuan Lo-Ciganic; Mini E Jacob; Sarah E Woody; Molly B Conroy; C Kent Kwoh; Steven M Albert; Robert Boudreau; Anne B Newman; Janice C Zgibor
Journal:  Res Gerontol Nurs       Date:  2015-10-26       Impact factor: 1.571

Review 5.  Exploring issues in difficult-to-treat hypertension.

Authors:  Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-10-30       Impact factor: 3.738

6.  Generic medications and blood pressure control in diabetic hypertensive subjects: results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.

Authors:  Doyle M Cummings; Abraham J Letter; George Howard; Virginia J Howard; Monika M Safford; Valerie Prince; Paul Muntner
Journal:  Diabetes Care       Date:  2012-11-12       Impact factor: 19.112

7.  Serum lipid profile and its association with hypertension in Bangladesh.

Authors:  Kamrun Nahar Choudhury; A K M Mainuddin; Mohammad Wahiduzzaman; Sheikh Mohammed Shariful Islam
Journal:  Vasc Health Risk Manag       Date:  2014-06-30

8.  Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007-2010.

Authors:  Shia T Kent; Daichi Shimbo; Lei Huang; Keith M Diaz; Meredith L Kilgore; Suzanne Oparil; Paul Muntner
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

9.  Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended.

Authors:  Xianglin L Du; Lara M Simpson; Brian C Tandy; Judy Bettencourt; Barry R Davis
Journal:  Int J Hypertens       Date:  2021-12-09       Impact factor: 2.420

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.